Inhaled Ciclesonide Study in Preterm Infants

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Bronchopulmonary Dysplasia
Interventions
DRUG

Alvesco Inhalant Product

Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.

Trial Locations (1)

64108

RECRUITING

Children's Mercy Kansas City, Kansas City

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Children's Mercy Hospital Kansas City

OTHER

NCT06589245 - Inhaled Ciclesonide Study in Preterm Infants | Biotech Hunter | Biotech Hunter